Explore 3 Stock Ideas & Industry Insights Download Free Report

Company price
0.98 USD -0.06 ( 5.77%)
Last update at 2026-11-19T21:00:00Z
VOLUME
15933
Market Cap
8.58M

Momentum Score

…

Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.98
Low
1.04
High
52 Week Price Range
1.05
Low
9.48
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Exicure is a clinical-stage biotechnology company developing therapies using spherical nucleic acids (SNAs) aimed at neurological and inflammatory diseases. Long-term growth drivers include clinical advancement of SNA candidates and the platform's potential to improve cellular delivery, which may support partnerships and address unmet medical needs.
Key risks are typical of clinical-stage biotechs: no approved products, significant clinical and regulatory uncertainty, and likely need for additional financing that could dilute shareholders.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.04
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
1.26M
Debt / Equity
0.04
ROE
-168.37%
Net Debt
-3.57M
ROCE
-54.95%
Diluted EPS TTM
-1.22

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -5.58M -9.69M -16.91M -2.37M -64.10M
Net income -4.95M -9.70M -16.91M -2.58M -65.78M
Selling general administrative 6.83M 5.45M 12.65M 10.89M 13.09M
Gross profit -0.46M 0.50M -1.42M 28.83M -0.48M
Reconciled depreciation 0.46M 0.82M 1.38M 1.86M 1.78M
Ebit -5.58M -9.68M -16.91M -1.83M -62.55M
Ebitda -5.12M -8.85M -15.54M -1.86M -60.64M
Depreciation and amortization 0.46M 0.82M 1.38M -0.03M 1.91M
Operating income -10.12M -12.23M -15.00M -1.83M -62.55M
Other operating expenses 10.12M 12.73M 15.00M 30.66M 62.07M
Interest expense 0.00M 0.02M 0.00M 0.59M 1.69M
Tax provision -0.63M 0.01M 0.00M 0.21M 0.00M
Interest income 0.03M 0.01M 0.03M 0.01M 0.14M
Net interest income 0.03M -0.01M 0.03M -0.58M -1.55M
Income tax expense -0.63M 0.01M -16.91M 0.21M 1.68M
Total revenue 0.00M 0.50M 0.00M 28.83M -0.48M
Total operating expenses 9.66M 12.73M 13.57M 30.66M 62.07M
Cost of revenue 0.46M 0.82M 1.42M - -
Total other income expense net 4.54M 2.54M -1.92M -0.54M -1.55M
Net income from continuing ops -4.95M -9.70M -16.91M -2.58M -64.10M
Net income applicable to common shares - - - -2.58M -64.10M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 14.04M 15.06M 11.58M 23.33M 64.87M
Intangible assets 3.78M - - - -
Other current assets 0.82M 0.64M 0.96M 1.47M 1.28M
Total liab 10.12M 8.28M 8.55M 8.41M 53.64M
Total stockholder equity 3.93M 6.77M 3.03M 14.92M 11.23M
Other current liab 2.02M 1.32M 0.25M 0.74M 6.00M
Common stock 0.00M 0.00M 0.00M - 0.01M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.01M
Retained earnings -204.21M -199.26M -189.56M -172.65M -170.07M
Other liab - - - - 12.16M
Good will 4.40M 0.00M - - -
Other assets - - - 3.49M 9.32M
Cash 3.75M 12.51M 0.82M 8.58M 34.64M
Total current liabilities 3.89M 3.07M 2.51M 1.64M 34.07M
Current deferred revenue - - - - 17.32M
Net debt -3.57M -6.57M 5.85M -1.27M -19.91M
Short term debt 0.18M 0.72M 0.63M 0.54M 7.33M
Short long term debt - - - - 6.87M
Short long term debt total 0.18M 5.93M 6.67M 7.31M 14.74M
Other stockholder equity 208.14M 206.03M 192.59M 187.57M 181.29M
Property plant equipment - - - 9.79M 11.88M
Total current assets 4.62M 13.67M 2.02M 10.05M 43.67M
Net tangible assets - - - 14.92M 11.23M
Short term investments - - - 0.00M 4.50M
Net receivables 0.06M 0.52M 0.25M - 0.00M
Inventory - - -0.25M - -
Accounts payable 1.69M 1.03M 1.63M 0.36M 3.41M
Accumulated other comprehensive income -0.00M - - - -0.00M
Non currrent assets other 0.93M 1.36M 1.78M 3.49M 9.32M
Non current assets total 9.42M 1.38M 9.56M 13.28M 21.20M
Capital lease obligations 0.18M 5.93M 6.67M 7.31M 7.86M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.00M -1.08M 4.70M 44.05M
Change to liabilities - - - -31.88M 22.07M
Total cashflows from investing activities -1.81M - -1.08M 4.70M 43.09M
Net borrowings 0.00M 1.00M 0.00M -7.50M -10.00M
Total cash from financing activities 1.60M 13.40M 3.67M -3.10M 1.12M
Change to operating activities - - - -4.94M 2.03M
Net income -4.95M -9.70M -16.91M -2.58M -64.10M
Change in cash -8.76M 10.49M -7.76M -34.07M 9.38M
Begin period cash flow 12.51M 2.02M 9.78M 43.84M 34.46M
End period cash flow 3.75M 12.51M 2.02M 9.78M 43.84M
Total cash from operating activities -8.55M -2.91M -10.36M -35.66M -34.82M
Issuance of capital stock 1.60M 12.40M 5.44M 5.04M 11.49M
Depreciation 0.46M 0.82M 1.38M 1.86M 1.78M
Other cashflows from investing activities -1.81M - 0.92M - -
Change to inventory - - - - 2.03M
Change to account receivables 1.34M -0.51M 0.00M 0.00M 0.01M
Sale purchase of stock - - -0.80M - -
Other cashflows from financing activities 1.60M - -1.77M -0.65M -0.37M
Change to netincome - - - 1.41M 3.12M
Capital expenditures 0.00M 0.00M 0.00M 0.01M 0.97M
Change in working capital 1.14M 0.63M 0.91M -36.81M 24.11M
Stock based compensation 0.00M 0.02M 1.35M 1.37M 2.94M
Other non cash items -4.58M 5.31M 2.92M 0.51M 0.29M
Free cash flow -8.56M -2.91M -10.36M -35.67M -35.79M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
XCUR
Exicure Inc
-0.06
5.77%
0.98 - - 13.61 9.11 27.17 -0.04
NVO
Novo Nordisk A/S
-0.54
1.36%
38.90 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-
-%
520.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
2.34
0.25%
923.34 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Exicure Inc

Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.

400 Seaport Court, Redwood City, CA, United States, 94063

847 673 1700

1

Name Title Year Born
Dr. Matthias G. Schroff Ph.D. CEO, Pres & Director 1968
Mr. Elias D. Papadimas CFO & Corp. Sec. 1976
Ms. Sarah Longoria Chief HR & Compliance Officer 1982
Mr. Bart Anderson Sr. Director of R&D NA
Mr. Paul Kang CEO & Director 1962
Ms. Jiyoung Hwang CFO & Director 1977
Mr. Joshua Miller Chief Accounting Officer 1976
Mr. Bart Anderson Senior Director of R&D NA
Mr. Jungsoo Kim CEO, President & Director 1973
Mr. Gyuyeob Lee Interim CFO & Secretary 1986

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…